NO20072882L - Defekte influensaviruspartikler. - Google Patents
Defekte influensaviruspartikler.Info
- Publication number
- NO20072882L NO20072882L NO20072882A NO20072882A NO20072882L NO 20072882 L NO20072882 L NO 20072882L NO 20072882 A NO20072882 A NO 20072882A NO 20072882 A NO20072882 A NO 20072882A NO 20072882 L NO20072882 L NO 20072882L
- Authority
- NO
- Norway
- Prior art keywords
- influenza virus
- influenza
- defective
- nucleic acid
- provides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16141—Use of virus, viral particle or viral elements as a vector
- C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
- C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16161—Methods of inactivation or attenuation
- C12N2760/16162—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04105696 | 2004-11-11 | ||
US62687804P | 2004-11-12 | 2004-11-12 | |
EP05105708 | 2005-06-27 | ||
US69443105P | 2005-06-28 | 2005-06-28 | |
PCT/EP2005/055808 WO2006051069A2 (en) | 2004-11-11 | 2005-11-08 | Defective influenza virus particles |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20072882L true NO20072882L (no) | 2007-08-03 |
Family
ID=36228630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20072882A NO20072882L (no) | 2004-11-11 | 2007-06-06 | Defekte influensaviruspartikler. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20080292658A1 (es) |
EP (2) | EP1812564A2 (es) |
JP (2) | JP4986859B2 (es) |
KR (1) | KR20070100882A (es) |
AU (1) | AU2005303817B8 (es) |
CA (1) | CA2587451A1 (es) |
IL (2) | IL182817A (es) |
MX (1) | MX2007005719A (es) |
NO (1) | NO20072882L (es) |
NZ (1) | NZ555118A (es) |
WO (1) | WO2006051069A2 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100964413B1 (ko) | 2001-01-19 | 2010-06-15 | 비로노바티브 비.브이. | 감응성 포유류에서 호흡계 질환을 유발하는 바이러스 |
WO2002068632A2 (en) | 2001-02-23 | 2002-09-06 | Wisconsin Alumni Research Foundation | Methods to identify mutant cells with altered sialic acid |
AU2003219745B8 (en) | 2002-02-13 | 2008-10-09 | Wisconsin Alumni Research Foundation | Signal for packaging of influenza virus vectors |
EP2327418A1 (en) | 2002-02-21 | 2011-06-01 | MedImmune, LLC | Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from other viruses |
US7682619B2 (en) | 2006-04-06 | 2010-03-23 | Cornell Research Foundation, Inc. | Canine influenza virus |
GB2437799B (en) * | 2006-05-24 | 2008-08-13 | Univ Warwick | Defective interfering virus |
EP2019685B1 (en) | 2006-05-24 | 2014-11-12 | The University Of Warwick | Defective interfering virus |
WO2008021415A2 (en) * | 2006-08-14 | 2008-02-21 | Massachusetts Institute Of Technology | Glycan data mining system |
US8597661B2 (en) | 2007-05-04 | 2013-12-03 | Wisconsin Alumni Research Foundation | Neuraminidase-deficient live influenza vaccines |
GB0822672D0 (en) | 2008-12-12 | 2009-01-21 | Univ Warwick | Anti-viral protection with viruses containing a defective genome |
JP2014527799A (ja) | 2011-08-26 | 2014-10-23 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | 変異型pb2遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス |
JP6431477B2 (ja) | 2012-05-10 | 2018-12-05 | マサチューセッツ インスティテュート オブ テクノロジー | インフルエンザの中和のための薬剤 |
EP3022298B1 (en) * | 2013-07-19 | 2019-06-19 | University Of Rochester | Attenuated influenza vaccines and uses thereof |
GB2522615A (en) | 2014-01-16 | 2015-08-05 | Univ Warwick | Assay and medicament |
US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
US10323231B2 (en) | 2015-04-24 | 2019-06-18 | University Of Rochester | Attenuated influenza vaccines and uses thereof |
EP3341018A1 (en) | 2015-08-28 | 2018-07-04 | Wisconsin Alumni Research Foundation | Generation of infectious influenza viruses from virus-like particles |
CL2018003871A1 (es) * | 2018-12-28 | 2021-01-15 | Univ Pontificia Catolica Chile | Anticuerpos monoclonales específicos para el antígeno pb2 del virus de la influenza humana (flu), secuencias nucleotídicas; método y kit de diagnóstico de infección producida por flu |
WO2020163804A1 (en) | 2019-02-08 | 2020-08-13 | Wisconsin Alumni Research Foundation (Warf) | Humanized cell line |
WO2021041624A2 (en) | 2019-08-27 | 2021-03-04 | Yoshihiro Kawaoka | Recombinant influenza viruses with stabilized ha for replication in eggs |
WO2023138651A1 (en) * | 2022-01-19 | 2023-07-27 | Versitech Limited | Rationally designed single-round infectious virus and methods of use thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5166057A (en) * | 1989-08-28 | 1992-11-24 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand rna virus expression-systems |
JP2003508086A (ja) * | 1999-07-30 | 2003-03-04 | アイシス イノヴェイション リミテッド | ワクチンとして有用な弱毒化インフルエンザウイルス |
US8012736B2 (en) * | 2002-04-26 | 2011-09-06 | Medimmune, Llc | Multi plasmid system for the production of influenza virus |
US7078218B2 (en) * | 2002-12-13 | 2006-07-18 | Alphavax, Inc. | Alphavirus particles and methods for preparation |
JP2007525175A (ja) * | 2003-04-23 | 2007-09-06 | ウィスコンシン アルムニ リサーチ ファウンデイション | 突然変異した膜タンパク質をその機能性の一部ウイルス |
-
2005
- 2005-11-08 US US11/667,594 patent/US20080292658A1/en not_active Abandoned
- 2005-11-08 AU AU2005303817A patent/AU2005303817B8/en not_active Ceased
- 2005-11-08 KR KR1020077013149A patent/KR20070100882A/ko active IP Right Grant
- 2005-11-08 EP EP05801665A patent/EP1812564A2/en not_active Ceased
- 2005-11-08 JP JP2007540638A patent/JP4986859B2/ja not_active Expired - Fee Related
- 2005-11-08 MX MX2007005719A patent/MX2007005719A/es active IP Right Grant
- 2005-11-08 EP EP10182312A patent/EP2272950A3/en not_active Withdrawn
- 2005-11-08 CA CA002587451A patent/CA2587451A1/en not_active Abandoned
- 2005-11-08 NZ NZ555118A patent/NZ555118A/en not_active IP Right Cessation
- 2005-11-08 WO PCT/EP2005/055808 patent/WO2006051069A2/en active Application Filing
-
2007
- 2007-04-26 IL IL182817A patent/IL182817A/en not_active IP Right Cessation
- 2007-06-06 NO NO20072882A patent/NO20072882L/no not_active Application Discontinuation
-
2012
- 2012-01-27 JP JP2012015022A patent/JP2012110339A/ja not_active Withdrawn
- 2012-02-20 IL IL218203A patent/IL218203A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2587451A1 (en) | 2006-05-18 |
MX2007005719A (es) | 2007-10-04 |
WO2006051069A3 (en) | 2006-07-20 |
IL182817A (en) | 2012-04-30 |
WO2006051069A2 (en) | 2006-05-18 |
EP2272950A2 (en) | 2011-01-12 |
AU2005303817B2 (en) | 2010-06-10 |
JP4986859B2 (ja) | 2012-07-25 |
EP2272950A3 (en) | 2011-07-20 |
IL182817A0 (en) | 2007-08-19 |
KR20070100882A (ko) | 2007-10-12 |
EP1812564A2 (en) | 2007-08-01 |
US20080292658A1 (en) | 2008-11-27 |
JP2012110339A (ja) | 2012-06-14 |
AU2005303817B8 (en) | 2010-09-30 |
NZ555118A (en) | 2009-09-25 |
JP2008519591A (ja) | 2008-06-12 |
IL218203A0 (en) | 2012-04-30 |
AU2005303817A1 (en) | 2006-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20072882L (no) | Defekte influensaviruspartikler. | |
ATE554789T1 (de) | Neues hundeinfluenza-virus und imfpstoff hierfür | |
UA94717C2 (ru) | Модифицированный вирус гриппа, предназначенный для мониторинга и повышения эффективности вакцины | |
WO2007095318A3 (en) | Influenza antigens, vaccine compositions, and related methods | |
AU2009303758A8 (en) | Benzoquinoline inhibitors of vesicular monoamine transporter 2 | |
WO2007118206A3 (en) | Canine influenza virus | |
WO2007126810A3 (en) | High titer recombinant influenza viruses for vaccines | |
TW200732476A (en) | Functional influenza virus like particles (VLPs) | |
ES2510940A2 (es) | Composición farmacéutica combinada y su uso para preparar un medicamento destinado al tratamiento y prevención de las enfermedades infecciosas | |
MX2010003202A (es) | Metodo para producir virus de la gripe. | |
NO20063693L (no) | Forbindelse og metode for anvendelse | |
NO20082149L (no) | Hundeinfluensavirus og relaterte sammensetninger og fremgangsmater for bruk | |
EA201100795A1 (ru) | Фармацевтическая композиция эффективного ингибитора всг для перорального введения | |
CY1113449T1 (el) | Αντι-ιικες συνθεσεις που περιλαμβανουν γερανιολη και καρβονη | |
NO20082124L (no) | Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom | |
NO20090723L (no) | Kondenserte heterosykliske derivater og fremgangsmater for anvendelse | |
WO2009026465A3 (en) | Composition and methods of making and using influenza proteins | |
MX2012000036A (es) | Vacuna. | |
IL186611A0 (en) | Vaccine against pandemic strains of influenza viruses | |
EA202090984A1 (ru) | Диспергируемая в полости рта единица дозирования, содержащая эстетрольный компонент | |
WO2011158044A3 (en) | Respiratory formulations containing p38 mapk inhibitors | |
WO2006115843A3 (en) | Nipah virus vaccines | |
NO20075961L (no) | Materialer og fremgangsmater til kontroll av respiratorisk sykdom hos hundedyr | |
MY143221A (en) | Orodispersible pharmaceutical composition for oromucosal or sublingual administration of agomelatine | |
JP2009511080A5 (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: ABBOT BIOLOGICALS BV, NL Owner name: ERASMUS UNIVERSITY MEDICAL CENTER, NL |
|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |